HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 279, Issue 24, 25905-25915, June 11, 2004

This Article Abstract Full Text (PDF) All Versions of this Article: 279/24/25905    most recent M400933200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Champagne, C. Articles by Lavoie, J. N. Search for Related Content PubMed PubMed Citation Articles by Champagne, C. Articles by Lavoie, J. N. Social Bookmarking                      What's this?

Activation of Adenovirus Type 2 Early Region 4 ORF4 Cytoplasmic Death Function by Direct Binding to Src Kinase Domain^*

Claudia Champagne, Marie-Claude Landry, Marie-Claude Gingras, and Josée N. Lavoie¶

From the Centre de Recherche en Cancérologie de l'Université Laval, L'Hôtel-Dieu de Québec, CHUQ, Québec G1R 2J6, Canada

Received for publication, January 28, 2004 , and in revised form, April 2, 2004.

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Adenovirus type 2 (Ad2) early region 4 ORF4 (E4orf4) triggers a major death pathway that requires its accumulation in cellular membranes and its tyrosine phosphorylation. This program is regulated by Src family kinases and triggers a potent ZVAD (benzyloxycarbonyl-VAD)- and Bcl2-resistant cell death response in human-transformed cells. How E4orf4 deregulates Src-dependent signaling is unknown. Here we provide strong evidence that a physical interaction requiring the kinase domain of Src and the arginine-rich motif of E4orf4 is involved. The Src binding domain of E4orf4 overlaps with, but is distinct from that of the B subunit of protein phosphatase 2A (PP2A-B) and some E4orf4 complexes contain both PP2A and Src. Functional assays using mutant E4orf4 revealed that deregulation of Src signaling, activation of the Jun kinase pathway, and cell blebbing were all critically dependent on Src binding. In contrast, PP2A-B binding per se was not required to engage the Src-dependent death pathway but was more critical for triggering a distinct death activity. Both E4orf4 death activities were manifested within a given cell population, were typified by distinct morphological features, and contributed to overall cell killing, although to different extents in various cell types. We conclude that E4orf4 binding to the Src kinase domain leads to deregulation of Src signaling and plays a crucial role in induction of the cytoplasmic death pathway. Nonetheless, both Src and PP2A enzymes are critical targets of E4orf4 that likely cooperate to trigger E4orf4-induced tumor cell killing and whose relative contributions may vary in function of the cellular background.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The adenovirus type 2 (Ad2)¹ early region 4 ORF 4 (E4orf4) is a 14-kDa early viral gene product whose function remains ill defined. E4orf4 is not essential for viral growth, although several activities were reported during viral infection that were linked to its ability to interact with cellular PP2A. However, the exact consequence on PP2A activity remains unclear (1-6). It is believed but not proven that E4orf4 cooperates with other viral products to trigger cell death at the end of the infectious cycle to propagate viral progeny (7). In mammalian cells, over-expression of E4orf4 triggers p53-independent cell death, and evidence accumulates that E4orf4 killing is much higher in transformed and cancer cells (7-11). Because, adenoviral infection drives a process similar to cell transformation by stimulating proliferation and inhibiting p53-dependent cell death, it is conceivable that E4orf4 has evolved to act in a transformed-like genetic background. Deciphering the mechanisms involved in cell death induction is of great interest, because they may unravel ways to manipulate oncogene signaling to trigger tumor-selective death programs.

Emerging evidence suggests that E4orf4 has several activities, some of which are cell type-specific. The specific localization of E4orf4 to the cytoplasm, cytoskeleton, and the nucleus illustrates the complexity of E4orf4 signaling with a number of potentially important cellular targets (12, 13). Caspase-dependent apoptosis was observed in specific cell lines, but E4orf4-induced cell death generally proceeds independently of the classical pathways for apoptosis induction (death receptor and mitochondrial pathways) (14, 15). Indeed in most transformed and cancer cells, E4orf4 triggers a ZVAD (benzyloxycarbonyl-VAD)- and Bcl-2-resistant cell death pathway associated with some features of apoptosis, including externalization of phosphatidylserines, cell and nuclear shrinkage, chromatin condensation, and phagocytosis by neighboring cells (8, 12, 15).² We have shown that this cell death pathway is associated with E4orf4 accumulation in the cell membrane-cytoskeleton and is first manifested by the appearance of dramatic actin changes leading to dramatic cell blebbing (12). This so-called cytoplasmic death activity is regulated by Src tyrosine kinases, requires the tyrosine phosphorylation of E4orf4, and involves the calcium-regulated cysteine proteases calpains (13, 15). Importantly, we have shown that E4orf4 targeting to cellular membranes recapitulates the Src-dependent death activity (15), suggesting that tyrosine-phosphorylated E4orf4 acts by disrupting some critical tyrosine kinase signaling pathway on membranes. A distinct death activity was also observed, in the absence of E4orf4 tyrosine phosphorylation (15). This death program was rather associated with E4orf4 accumulation in the cell nucleus and led to a distinct morphological phenotype, characterized by dramatic cell shrinkage in the absence of early blebbing induction. The nuclear targets of E4orf4 remain unknown, but may be related to its ability to trigger an irreversible G₂/M growth arrest in yeasts and in specific cancer cell lines (16, 17). Notably, E4orf4 killing and growth inhibition was shown to depend on its ability to bind to the regulatory subunit B of protein phosphatase 2A (PP2A-B) and recruit PP2A phosphatase activity (10, 16-18). Whether E4orf4 acts by inhibiting and/or stimulating PP2A activity toward specific substrates in a way that relies on recruitment to PP2A-B to specific cell compartments remains unclear. Whatever the case, these studies indicated that extra functions are required for cell killing and that some PP2A-independent killing also exists. Although it is clear that E4orf4 possesses distinct activities in various cell types, the functional relationship between Src and PP2A was not addressed, and the molecular mechanisms involved in engagement of the so-called cytoplasmic death pathway remain elusive.

We have delineated the determinants of E4orf4-Src association at the molecular level. E4orf4 mutant proteins were used to address the role of Src and PP2A-B binding in induction of the cytoplasmic death pathway typified by early changes in actin dynamics. The results strongly suggest that a physical interaction with the kinase domain of Src-like tyrosine kinases is critical to activate E4orf4 cytoplasmic death functions. This interaction requires a highly basic motif on E4orf4 that overlaps with, but is distinct from, the PP2A-B binding site. Based on the available data, E4orf4 binding to PP2A-B per se is dispensable for deregulation of Src signaling and activation of the cytoplasmic death pathway and appears more critical for induction of a distinct death program.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Expression Vectors and Mutagenesis—The following expression vectors were described previously: Ad2 HA-E4orf4 (8); FLAG-E4orf4 (13); Myc-E4orf4 (12); FLAG-E4orf4-green-fluorescent protein (GFP) and FLAG-GFP-NLS (15); GST-SH2^v-Src and GST-SH3^v-Src (designated SH2v and SH3v) and Myc-p130Cas from Dr. Michel Tremblay, McGill University, Montreal, Canada (19, 20); GST-c-Src, GST-SH2^c-Src, and GST-c-SrcSH2 (13); polyomavirus middle T-antigen (mT); and MT20010 from Dr. Stephen M. Dilworth, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK (21); Myc-FAK from Dr. J. Thomas Parson, University of Virginia School of Medicine, Charlottesville (22); chicken c-Src (Y527F) in pLNCX from Dr. Joan S. Brugge, Harvard Medical School, Boston, MA (23); GFP-actin in pEGFP C2 (24); and FLAG-PP2A-B, Ad2 E4orf4 (R69A/R70A), (R73A/R74A/R75A), (R69A/R70A/R72A/R73A/R74A/R75A), (R81A/F84A), and (F84A) in pCDNA3 from Dr. Philip E. Branton, McGill University, Montreal, Quebec, Canada (18). The mutant E4orf4 (R69A/R70A/R72A/R73A/R74A/R75A) was designated (6R-A). E4orf4 (6R-A/R81A/F84A) was generated by PCR with the QuikChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's recommendations using E4orf4 (6R-A) as template with the following primers: 5'-TCT GTT TGT CAC GCC GCC ACC TGG GCT TGC TTC AGG AAA TAT GAC-3' and 5'-GTA GTC ATA TTT CCT GAA GCA AGC CCA GGT GGC GGC GTG ACA AAC-3'. FLAG-E4orf4 mutant constructs were generated from HA-E4orf4 mutants as described in Ref. 12. Untagged E4orf4 proteins were obtained by subcloning the HindIII-XhoI E4orf4 DNA fragments from HA-E4orf4 constructs into pCDNA3 vector. E4orf4-GFP constructs were produced by PCR amplification using HA-tagged versions and the following primers: 5'-AGA GGG CCC AG GTT CTT CCA GCT CTT CCA-3'and 5'-CTC CCC GGG CTG GAA CTG TGG CTC AGT-3'. The resulting DNA fragments were inserted in ApaI-XhoI sites of the FLAG-GFP vector (25). FLAG-E4orf4 (4YF)-GFP, designated nonphosphorylatable E4orf4 (E4orf4[NP]) was produced by site-directed mutagenesis, using FLAG-E4orf4(3YF)-GFP (13) as template and primers: 5'-GAG TGG ATA TTC TTC AAC TAC TAC ACA GAG-3' and 5'-GTA GTA GTT GAA GAA TAT CCA CTC TCT CAA-3'. GFPE4orf4 (amino acids 62-79) and (amino acids 62-95) were from Dr. Philip E. Branton, McGill University, Montreal, Quebec, Canada and were generated by adding the sequence corresponding to amino acids 62-79 or 62-95 of E4orf4 to GFP by standard PCR techniques using the following primers: sense, 5'-CGC GGA TCC ATG GTG AGC AAG GGC GAG GAG-3' and antisense for 62-79, 5'-CGC GAA TTC CTA GTG ACA AAC AGA TCT GCG TCT CCG GTC TCG TCG CTT AGC TCG CTC TGT GTA GTA CTT GTA CAG CTC GTC CAT GCC GAG AG-3' or antisense for 62-95, 5'-CGC GAA TTC CTA GGA ACG CCG GAC GTA GTC ATA TTT CCT GAA GCA AAA CCA GGT GCG GGC GTG ACA AAC AGA TCT G-3'. The resulting fragments were inserted in pCDNA3. GST-FLAG-E4orf4 was generated by PCR using FLAG-E4orf4 as template and the sense and antisense oligonucleotides 5'-GG GGT ACC ATG GTT CTT CCA GCT CTT CC-3' and 5'-ATT TAG GTG ACA CTA TAG-3' (SP6 primer). The resulting DNA fragment was subcloned in SmaI-BamHI sites of pGEX6P-1 (Amersham Biosciences). GST-SH3c was generated by PCR using pCI-neo-c-Src (12) as template and the primers: 5'-CCGGAATTCC ACC ACC TTT GTG GCC CTC TA-3' and 5'-TTGCGGCCGCCC CTA GGA GGG CGC CAC ATA GT-3'. GST-SH3c was generated by PCR extension overlap (to join amino acids Val⁸⁵ to Glu¹⁴⁸ of c-Src sequence) using paired sense and anti-sense primers 5'-CCACAGGTGTCCACT-3' and 5'-CCA CTC CTC CAC CCC ACC TGC CAG AGG CCC-3' and 5'-GGT GGG GTG GAG GAG TGG TAC TTT GGC AAG-3' and 5'-CTAGTTGTGGTTTGTCC-3'. The resulting fragment was subcloned in EcoRI-NotI sites of pGEX4T-3 (Amersham Biosciences) and pCI-neo (Promega) vectors. The kinase (SH1) domain of c-Src was excised by PCR using the sense and anti-sense primers: 5'-CC GGA ATT CG ATG GCG TGG GAG ATC CCC CG-3' and 5'-CTAGTTGTGGTTTGTCC-3' and was subcloned in EcoRI-NotI sites of pGEX4T-3 and pCI-neo. To generate c-Src SH1, the pGEX-4T-3/c-Src and pCI-neo-c-Src were treated with XmaI-S1 nuclease, and the resulting DNA fragments were ligated to join Pro²⁶⁵ to Glu⁵³³ of c-Src. All mutations and DNA fragments generated by PCR were confirmed by DNA sequence analysis.

Cell Culture, Transfections, and Functional Assays—293T cells were derived from human embryonic kidney cells, although this cell line may be of neuronal origin (26) and express Ad5 E1A and E1B proteins and large T antigen (27). Human C-33A (American Type Culture Collection, HTB-31) is from cervical carcinoma. 293T and C-33A were maintained in Dulbecco's modified Eagle medium and in -modified Eagle's medium, respectively, both supplemented with 10% fetal bovine serum and streptomycin sulfate-penicillin (100 units/ml). Transfections of 293T were performed by the calcium phosphate method in culture dishes coated with polylysine as described (12, 15). C-33A cells were transfected using GeneSHUTTLE-40 (Qbiogene, Inc.), according to the manufacturer's recommendations. In vivo localization of GFP proteins was performed using a Nikon TE-200 inverted microscope equipped with a CO₂/thermoregulated chamber and a x40 0.6 numerical aperture (NA) objective. Images were captured as 16-bit TIFF files with a Photometrix Coolsnap FX cooled CCD camera (-30 °C) (Rooper Scientific, Tucson, AZ) driven by Metaview software version 4.5 (Universal Imaging Corp., Downingtown, PA). Confocal microscopy was performed using a Bio-Rad MRC-1024 imaging system mounted on a Nikon Diaphot-TMD with x20 (zoom x3) or x60 0.85 NA (zoom x1.84) objective lens. The blebbing inducing activity and chromatin condensation were determined as described (13). Briefly, cells were gently washed in PBS containing 1 mM MgCl₂ and 0.5 mM CaCl₂, fixed in 3.7% formaldehyde/PBS for 20 min, and permeabilized in 0.2% Triton X-100/PBS for 5 min. Immunodetection of HA-E4orf4, E4orf4-GFP, and untagged E4orf4 was performed using mouse HA.11 anti-HA antibody (Sigma-Aldrich), rabbit anti-GFP (Clontech), or rabbit 2419 anti-E4orf4, respectively, followed by Alexa 594- or Alexa 488-labeled goat anti-rabbit IgG (Molecular Probes), and staining of DNA was performed using 4'-6-diamidino-2-phenylindole dihydrochloride (DAPI, Molecular Probes). Long-term cell killing was determined by colony-forming assays as described (13). When indicated, the broad spectrum caspase inhibitor Boc-Asp-(OMe)-CH₂F (BocD-fmk, Calbiochem) was added to the culture medium at 15 µM during transfection and at 30 µM after transfection. Fresh inhibitor was added back every 24 h.

GST Fusion Proteins and in Vitro Binding Assays—GST-c-Src constructs were introduced in Escherichia coli BL21 strain expressing GroES and GroEL chaperones encoded by pRep4-GroESL vector (a generous gift from Drs. Kurt Amrein and Martin Stieger, Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ) (28). The fusion proteins were produced by growing bacterial cultures to an OD₆₀₀ of between 0.6 and 0.8 followed by a treatment with 0.1 to 0.5 mM isopropyl--D-galactopyranoside for 2-6 h at 30 °C. Bacteria were recovered by centrifugation and kept at -20 °C overnight. Bacterial pellets were thawed at room temperature and lysed as described (13). The supernatants were incubated with glutathione-Sepharose 4B beads for 2 h at 4 °C, and the beads were washed three times in washing buffer (PBS containing 1% Triton X-100 and 1 mM EDTA). To remove the bound chaperones, beads were incubated in ATP buffer (50 mM Tris-HCl, pH 7.4, 10 mM MgSO₄, and 2 mM ATP) for 20 min at 37 °C, washed three times in washing buffer, and used for in vitro binding assays. The amount of purified proteins was evaluated on a Coomassie Blue-stained gel. In vitro binding assays were performed as described (13) by incubating equal amounts of transfected total cell lysates (1 mg) with 5 µg of freshly prepared immobilized GST fusion proteins overnight at 4 °C. The beads were recovered by centrifugation, washed once in lysis buffer, then twice in lysis buffer containing only 0.1% Nonidet P-40, and boiled in sodium dodecyl sulfate (SDS) sample buffer. Bound proteins were analyzed by Western blot analysis with the appropriate antibody. The GST-FLAG-E4orf4 was produced as described (12). The GST moiety was removed by incubating the beads in protease buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, and 4 units of PreScission Protease^TM (Amersham BioSciences)) overnight at 4 °C with rotation. Recombinant FLAG-E4orf4 protein was recovered in the supernatant, and direct binding to c-Src kinase domain was performed using 5 µg of the indicated GST-c-Src proteins and 200 ng of purified FLAG-E4orf4 protein, as described above. In vitro kinase assays were performed using 250 ng of bound GST-c-Src and 2.5 µg of purified FLAG-E4orf4 or GST in kinase buffer (50 mM Hepes pH 7.4, 10 mM MgCl₂, 0.1% -mercaptoethanol, 0.1 mM Na₃Vo₄) containing 0.1 mM ATP and 10 µCi of [-P³²]ATP in a 50-µl reaction mixture. The reactions were allowed to proceed for 20 min at 30 °C and stopped by adding 25 µl of 3x SDS sample buffer. Labeled samples were resolved on SDS-PAGE and visualized by autoradiography or analyzed by Western blot after electrotransfer on nitrocellulose.

Immunoprecipitation, Western Blotting, and Antibodies—For coprecipitations, cells on 10-cm plates were lysed with 0.5 ml of modified radioimmune precipitation assay buffer (RIPA: 50 mM Hepes pH 7.4, 150 mM NaCl, 1.5 mM MgCl₂, 1 mM EGTA, 1% Triton, 1% sodium deoxycholate, 0.1% SDS, 10% glycerol, 50 mM NaF, 10 mM -glycerophosphate, 1 mM Na₃Vo₄, 15 µg/ml leupeptin, 5 µg/ml aprotinin, 1 µg/ml pepstatin A), and lysates were immediately diluted with 0.5 ml of HNTG buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 0.1% Triton X-100, and 10% glycerol), as described (29). The lysates were incubated with protein G-Sepharose (Amersham Biosciences) or protein G Plus-agarose (Oncogene Research Products) for 20 min on ice and cleared by centrifugation. Immunoprecipitation was carried out with mouse anti-FLAG M2 (Sigma-Aldrich), rabbit SRC2 anti-Src (Santa Cruz Biotechnology), mouse Ab1 anti-Src (Calbiochem), mAb 327 anti-c-Src (26), or rabbit 2419 anti-E4orf4 for 2.5 h at 4 °C. Immune complexes were collected on protein G-Sepharose or protein G Plus-agarose and washed three times in modified RIPA containing only 1% Triton X-100 before analysis on SDS-PAGE. Equal amounts of immune complexes were resolved on 9 or 11% SDS-PAGE, transferred to nitrocellulose, and processed for immunoblotting. To disrupt the antigen-antibody complex before reprobing, immunoblots were incubated in stripping buffer (62.5 mM Tris-HCl pH 6.7, 2% SDS, 100 mM -mercaptoethanol) for 30 min at 60 °C, washed in PBS-Tween (0.1%) at room temperature and reprocessed for immunoblotting. The following antibodies were used for immunoblotting analyses: mouse anti-cortactin (4F11, Upstate Biotechnology); mouse anti-FLAG (M2, Sigma); mouse anti-HA (HA.11, Babco); mouse anti-Myc (9E10, Sigma); mouse anti-polyomavirus middle T-antigen (Pab 762) (30); mouse anti-phosphotyrosine (RC20:HRPO, Transduction Laboratories); rabbit anti-Src (SRC2, Santa Cruz Biotechnology); mouse anti-phospho-Src (Tyr⁴¹⁶) (Cell Signaling, NEB), mouse anti-PP2A-C (clone46, BD Biosciences), rabbit anti-phospho-p-38 (Thr¹⁸⁰/Tyr¹⁸²) (Cell Signaling, NEB), rabbit anti-ERK2 (clone 856) (31), mouse E10 anti-phospho-p44/42 MAPK (Thr²⁰²/Tyr²⁰⁴) (Cell Signaling, NEB), rabbit H-79 anti-c-Jun (Santa Cruz Biotechnology), rabbit anti-phospho-c-Jun (Ser⁶³) II (Cell Signaling, NEB), mouse anti--actin (AC-74, Sigma-Aldrich), and rabbit 2419 anti-E4orf4. Rabbit 2419, 2418, and 2420 anti-E4orf4 antibodies were described (12). The anti-phospho-E4orf4 (Tyr⁴²) was produced by injecting rabbits with a chemically synthesized peptide comprising the phosphorylated Tyr⁴² (HEGVY[PO₃H₂]IEPEARGRLC), which was coupled to mcKLH (Imject Mariculture keyhole limpet hemocyanin, Pierce) following the manufacturer's recommendations. The serum was purified against the immobilized nonphosphorylated peptide (HEGVYIEPEARGRLC), was absorbed on immobilized phosphorylated peptide using the SulfoLink Kit (Pierce), and was finally purified against phosphotyrosines linked to agarose (O-phospho-L-tyrosine-agarose, Sigma-Aldrich) according to the manufacturer's recommendations. The specificity of the resulting anti-phospho-E4orf4 (Tyr⁴²) was tested by Western blot analysis of E4orf4 immune complexes and total cell lysates from 293T cells transfected with wild-type FLAG-E4orf4, compared with mutant FLAG-E4orf4 (Y42F) alone or together with c-Src or v-Src to induce maximum tyrosine phosphorylation of Ad2 E4orf4, as described (13). The antibody reacted specifically with wild-type Ad2 E4orf4 but not with mutant E4orf4 (Y42F), and the specific signal was proportional to the level of tyrosine phosphorylation.

	RESULTS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Ad2 E4orf4 Directly Interacts with the Kinase Domain of Src—In several transformed and cancer cell lines expressing Ad2 E4orf4, including 293T, C-33A, and H1299, a membrane-cytoskeleton fraction of E4orf4 is associated with Src family kinases, and inhibition of Src kinases interferes with cell death induction (12, 13, 15). To obtain further insight into how E4orf4 usurps Src kinases to trigger cell death, we sought to analyze the molecular determinants of E4orf4-Src interaction. To identify the interaction site on Src kinases, we produced functional recombinant GST fusion proteins containing the Src homology domain (SH) 1, SH2, SH3, or bearing deletions of c-Src regulatory sequences (SH), which is the prototype of the ubiquitously expressed cellular Src kinases, Src, Fyn, and Yes (reviewed in Ref. 32). In vitro binding assays were performed using cell lysates from 293T transfected with FLAG-E4orf4 or FLAG-GFP as a negative control for Src binding. Lysates from 293T transfected with polyomavirus middle T-antigen, FAK, or p130Cas were used as positive controls for binding to Src kinase domain (SH1), SH2, and SH3 domains, respectively. We found that c-Src kinase domain (SH1), but not the SH2 and SH3 domains, is required for E4orf4 binding (Fig. 1A). Coimmunoprecipitations using lysates from 293T cotransfected with FLAG-E4orf4 and c-Src mutants confirmed that Ad2 E4orf4 interacts with the kinase domain in vivo (Fig. 1B). Interestingly, significant E4orf4 binding to v-Src SH3 domain, but not c-Src SH3 domain, was also detected as previously reported for FAK (Fig. 1A, myc-FAK, left panel). Such an interaction is believed to facilitate a v-Src-FAK interaction in more invasive cells, which is cell adhesion- and SH2-independent. This interaction relies on residues in the RT loop region of the v-Src SH3 domain that differ from those of the c-Src SH3 domain (33, 34). The N-terminal sequence of Ad2 E4orf4 contains a proline-rich motif, PALPAPP, conforming to a v-Src SH3 binding consensus (PXXPXX where is a hydrophobic residue) (35). However, deletion of the E4orf4 Pro-rich motif did not ablate binding to Src kinases (data not shown). Consistently, deletion of c-Src SH3 had no effect, whereas deletion of the kinase domain (SH1c) ablated binding to c-Src in vitro (Fig. 1A). A recombinant GST-E4orf4 readily bound to full-length GST-c-Src and to GST-kinase^c-Src, but not to the kinase domain-deleted GST-c-Src (SH1c) or to GST alone, indicating that the interaction is direct (Fig. 1C). Furthermore, GST-c-Src could mediate the phosphorylation of recombinant E4orf4 in vitro (Fig. 1C, right panel). Immunoblot analysis of the in vitro-phosphorylated E4orf4, using a phosphospecific E4orf4 (Tyr⁴²) antibody raised against the major phosphorylated tyrosine in vivo (13) confirmed the specificity of phosphorylation. Altogether, the data provide strong support for a physical interaction between Ad2 E4orf4 and Src family kinases that primarily involves sequences residing within the kinase domain and may contribute to tyrosine phosphorylation of Ad2 E4orf4 in vivo.

View larger version (30K): [in this window] [in a new window]   FIG. 1. E4orf4 physically interacts with the kinase domain of c-Src. A, in vitro binding was performed using lysates from 293T cells transfected with FLAG-E4orf4, FLAG-GFP, mT, Myc-p130Cas, or Myc-FAK plus c-Src (Y527F), which were incubated with the indicated immobilized GST-c-Src fusion proteins, as depicted. The retained material was analyzed by Western blot using anti-FLAG (M2), anti-mT (Pab762), and anti-Myc (9E10) antibodies. The input lanes represent 1% of the total cell lysates (TL). Results are representative of three independent experiments. SH3v, v-Src SH3 domain; SH3c, c-Src SH3 domain; SH2c, c-Src SH2 domain; SH2v, v-Src SH2 domain; SH1c, c-Src kinase domain. B, 293T were transfected with FLAG-E4orf4 together with the indicated c-Src constructs. Cell were lysed and processed for immunoprecipitation (Ip) using anti-FLAG (M2). Immune complexes were analyzed by Western blot using the indicated antibodies. The amounts of transfected c-Src in total cell lysates (TL) are shown. NS, nonspecific band recognized by anti-SRC2. C, recombinant Ad2 FLAG-E4orf4 (200 ng) were incubated with 5 µg of the indicated GST fusion proteins, and the bound E4orf4 was revealed by Western blot using anti-FLAG M2 antibody (left panel). Ponceau S staining of the GST fusion proteins and Coomassie Blue-staining of purified GST and FLAG-E4orf4 are shown as loading controls. In vitro kinase assay was performed with purified FLAG-E4orf4 (2.5 µg) or GST (2.5 µg) and GST-c-Src (250 ng) (right panel). Labeled reaction mixtures were resolved by SDS-PAGE and visualized by autoradiography ([-32P]ATP) or analyzed by Western blot using anti-phospho-E4orf4 (Tyr42).

View larger version (44K): [in this window] [in a new window]   FIG. 2. A core Arg-rich motif on E4orf4 is required for binding to kinasec-Src in vitro. A, amino acid sequence alignments of residues 62-95 in wild-type and mutant Ad2 E4orf4 (18). Highlighted residues (bold) show the position of alanine substitutions. B and C, in vitro binding assays were performed using lysates from 293T cells transfected with the indicated untagged E4orf4 or GFP fusion proteins, which were incubated with immobilized GST-c-Src fusion proteins, as indicated. The retained material was analyzed by Western blot using anti-E4orf4 (2419) or anti-GFP. The input lanes represent 1 or 2% of the total cell lysates (TL). E4orf4 binding to kinasec-Src (SH1c) was quantitated using a 125I-labeled or peroxidase-conjugated goat anti-mouse or anti-rabbit to reveal the antigen-antibody complexes. Relative binding was estimated from scanned autoradiography derived images by densitometry analysis with NIH Image software (125I), or from FluorS MAX Multiimager-captured images using Quantity One® software (Bio-Rad). Percent binding to SH1 was calculated relative to the input levels of each E4orf4 proteins and is expressed relative to the binding of wild-type E4orf4 (100%). The data are the means ± S.D. of at least three independent experiments performed with N-terminal-tagged or -untagged E4orf4.

View larger version (55K): [in this window] [in a new window]   FIG. 3. E4orf4 association with c-Src in vivo is mediated by the Arg-rich motif and does not require PP2A-B binding. A, equal amounts of 293T cell lysates transfected with the indicated E4orf4 constructs or with the vector alone (EV) were processed for immunoprecipitation (IP) of endogenous c-Src using mab327 anti-c-Src. Immune complexes were analyzed by Western blot with anti-E4orf4 (2419) and anti-c-Src, and the amounts of transfected E4orf4 proteins are shown in total cell lysates (TL). B, immune complexes of E4orf4 were isolated from 293T cotransfected with the indicated E4orf4 constructs and FLAG-PP2A-B and were analyzed by Western blot using anti-FLAG (M2) and anti-E4orf4 (2419). The amounts of transfected E4orf4 proteins and PP2A-B in total cell lysates are shown (TL). Relative binding to endogenous c-Src (A) or exogenous PP2A-B (B) was estimated from scanned-derived images by densitometric analysis with Quantity One® software, and the percent binding is expressed relative to the binding of wild-type E4orf4 (100%). The data are the means ± S.D. of at least three independent experiments performed with untagged E4orf4 or FLAG-E4orf4 proteins (A) or performed with HAE4orf4 and untagged E4orf4 proteins (B).

Given that Src and PPP2A associations are mediated by overlapping sequences on E4orf4, we attempted to determine whether the binding of Src affects the binding of PP2A-B in vivo or vice versa. E4orf4 was coexpressed with large amounts of v-Src, and the recruitment of endogenous PP2A-C (PP2A catalytic subunit) by E4orf4 was evaluated by coprecipitations. In principle, interfering with PP2A-B binding should also interfere with the recruitment of PP2A-C. E4orf4 association with PP2A-C was not decreased and on the contrary was slightly promoted by v-Src. A similar effect was observed upon overexpressing PP2A-B (Fig. 4A). Given that Src and PP2A interact with one another in other systems (36-40), the recruitment of PP2A-C could be mediated by v-Src in this particular experiment. As another approach, we compared the ability of endogenous c-Src to associate with PP2A-C in the presence and absence of E4orf4. We repeatedly observed increased PP2A-C association with active c-Src in the presence of E4orf4 (Fig. 4B). This suggests that E4orf4 binding to both PP2A-B and c-Src exists, because increased Src binding to PP2A-C was likely mediated by the ability of E4orf4 to recruit PP2A holoenzyme by specific binding to the B subunit. Whatever the case, the data indicated that binding to Src and PP2A was not competitive. Reciprocally, overexpression of PP2A-B did not inhibit E4orf4 association with endogenous c-Src, and no significant competition for E4orf4 binding was observed, considering that overexpression of PP2A-B inhibited E4orf4 expression in cotransfection experiments (Fig. 4C). Altogether, the data suggest that at least part of the E4orf4 signaling complexes contain both c-Src and PP2A and that some cooperative signaling may exist in the context of the wild-type E4orf4 protein.

View larger version (44K): [in this window] [in a new window]   FIG. 4. E4orf4 binding to Src and PP2A is not competitive. A, overexpression of v-Src does not inhibit E4orf4 binding to PP2A. 293T were transfected with v-Src or PP2A-B alone (EV), or together with E4orf4 and immune complexes were isolated with anti-E4orf4 (2419) and analyzed by Western blot using anti-PP2A-C and anti-E4orf4 (2419). B, E4orf4 promotes c-Src binding to PP2A. 293T were transfected with E4orf4 or the vector alone (EV), immunoprecipitations (IP) of endogenous c-Src were performed using mab327 anti-c-Src, and immune complexes were analyzed by Western blot using anti-c-Src (mab327), anti-phospho-Src (Tyr416), and anti-PP2A-C. The amounts of transfected E4orf4 and endogenous PP2A-C in total cell lysates are shown (TL). C, excess PP2A-B does not inhibit E4orf4 binding to endogenous c-Src. 293T were transfected with high amounts of FLAG-PP2A-B alone (EV) or together with E4orf4. Immunoprecipitations of endogenous c-Src were performed using mab327 anti-c-Src, and the amounts of associated E4orf4 in immune complexes were analyzed by Western blot using anti-E4orf4 (2419). The levels of transfected E4orf4 in total cell lysates are shown (TL). The data are representative of at least three independent experiments, and identical results were obtained using anti-FLAG to isolate FLAG-E4orf4 immune complexes.

View larger version (33K): [in this window] [in a new window]   FIG. 5. E4orf4 binding to Src kinase domain is necessary and sufficient for modulation of Src-dependent phosphorylation. A, transfections were performed as indicated, and immune complexes of all Src species (endogenous Src kinases alone (-) or with exogenous kinasec-Src (+)) were isolated using a pan-Src antibody (SRC2) and were analyzed using anti-phosphotyrosine (pTyr), anti-cortactin (4F11) and anti-Src (SRC2). Levels of endogenous cortactin and exogenous FLAG-E4orf4 in total cell lysates are shown (TL). Note that the level of cortactin in immune complexes containing endogenous Src and mainly kinasec-Src (Kinc-Src) was equivalent to that in immune complexes of endogenous Src alone, in the absence of E4orf4. However, E4orf4 significantly promoted association of kinasec-Src with endogenous cortactin (asterisks) and other phosphotyrosine-containing proteins. B, equal amounts of cell lysates from 293T transfected with activated c-Src (Y527F) alone (EV) or together with wild type or the indicated mutant E4orf4 were analyzed by Western blot using RC20-HRP anti-phosphotyrosine (pTyr), anti-Src (SRC2), anti-E4orf4 (2419), or anti--actin. Arrows indicate major tyrosine-phosphorylated protein bands whose Src-dependent phosphorylation was increased by the wild-type and mutant E4orf4 defective in PP2A-B binding (R81/F84A, F84A), but not by mutant E4orf4 deficient in Src binding (6R-A) or nonphosphorylatable E4orf4 (4Y-F).

MAP kinases have been defined as essential mediators of survival and stress/death responses in several studies, generally linking the ERK1/2 pathway to survival and the stress-activated MAP kinase modules JNK and SAPK2/p38 to either death or survival, depending on the context and stimuli. MAP kinases are downstream targets of Src signaling, and specific regulation by Src was reported, depending on the cell type and the nature of the stimulus (reviewed in Refs. 44 and 45). Activation of ERK downstream of Src is a major effect of the transforming viral protein polyomavirus mT that also interacts with both PP2A and Src, and contributes to trigger cell transformation and survival by mT (reviewed in Ref. 46). Notably, mT interaction with Src kinases is also mediated by the kinase domain (47). To get further biological readouts of E4orf4-Src signaling and compare the specificity of E4orf4-Src versus mTSrc signaling, we analyzed the effect of E4orf4 on the activation state of the three major MAP kinase pathways in 293T cells. Western blot analyses of cell lysates from 293T transfected with E4orf4 or mT were performed using phosphospecific antibodies that recognize the active ERK1/2, SAPK2/p38, and phosphorylated c-Jun, as a measure of sustained JNK activation. None of the viral proteins had a significant effect on SAPK2/p38 activity in 293T. As expected, mT led to a potent activation of ERK and also increased c-Jun phosphorylation on Ser⁶³ in 293T cells, indicating that mT can increase the activity of two distinct non-intersecting MAP kinase pathways in the context of 293T (Fig. 6A). In marked contrast, E4orf4 did not activate ERK and a slight decrease of ERK activity was rather detected occasionally (Fig. 6A). The absence of ERK activation in E4orf4-expressing cells was consistent with the pro-death effect of E4orf4-Src signaling. Remarkably, E4orf4 expression was always associated with a robust activation of the JNK pathway leading to hyperphosphorylation of c-Jun. Mutant E4orf4 proteins that did not bind to the kinase domain of Src did not activate JNK (6R-A, 6R-A/R81A/F84A), whereas mutants defective for PP2A-B binding (R81A/F84A, F84A) retained the capacity to activate the JNK pathway (Fig. 6B). The mutant E4orf4 (R81A/F84A) was however less efficient relative to wild-type E4orf4, suggesting that Src and PP2A signaling might cooperate in JNK activation in the context of the wild-type E4orf4. Whatever the case, deregulation of Src signaling by E4orf4 was associated with a selective JNK activation, whereas mT led to qualitatively different output signaling by activating both ERK and JNK in 293T cells.

View larger version (51K): [in this window] [in a new window]   FIG. 6. Ad2 E4orf4 binding and modulation of Src lead to activation of the JNK pathway. A, 293T were transfected with E4orf4 or mT, and total cell lysates were analyzed by Western blot using anti-phospho-ERK (p-ERK), anti-phospho-c-Jun (p-c-Jun), or anti-phosphop-38. Immunoblots were stripped and reprobed with either the anti-ERK2, anti-c-Jun, or anti--actin, and the levels of mT and E4orf4 proteins in total cell lysates are also shown. B, 293T were transfected with the vector alone (EV), wild-type, or mutant E4orf4, as indicated. Hyperphosphorylation of c-Jun was analyzed by Western blot as described in A.

View larger version (63K): [in this window] [in a new window]   FIG. 7. Inhibition of Src binding, but not PP2A-B binding, abolishes the cytoplasmic death activity of Ad2 E4orf4. A, the cytoplasmic death activity was analyzed in 293T cells during the first 48 h after transfection. Blebbing was monitored by cotransfecting actin-GFP with E4orf4 constructs at a plasmid DNA ratio of 1:20, and the amounts of GFP-positive blebbing cells were determined by fluorescence microscopy in live cells 24 h after transfection (left panel). Data are expressed as percent blebbing cells relative to the total number of GFP-positive cells (right graph, light gray bars). Other cultures transfected with E4orf4 proteins only were fixed 48 h after transfection and processed for immunostaining of E4orf4 proteins and 4'-6-diamidino-2-phenylindole dihydrochloride (DAPI) labeling. Nuclear condensation was determined by counting the number of E4orf4-positive cells presenting nuclear shrinkage associated with intense chromatin condensation, and data are expressed relative to the total number of E4orf4-positive cells (dark gray bars). Aliquots of transfected cells were kept for Western blot analysis of expression levels (right inset). Data are the mean ± S.D. of at least three independent experiments, n > 1,000, and identical results were obtained using N-terminal-tagged or -untagged E4orf4 proteins, as well as E4orf4-GFP fusion proteins. Bars, 10 µm. B, 293T were transfected with pGKpuro together with either the vector only (EV), wild-type, or mutant E4orf4, as indicated, using a plasmid DNA ratio of 1:20, and cell survival assays were performed. Aliquots of transfected cells were kept for Western blot analyses of expression levels 24 h after transfection, before applying the selection for transfected cells (puromycin, 3 µg/ml). Percentages of surviving cells were obtained by counting the number of resulting colonies and are expressed relative to the total number of colonies obtained in cells transfected with the vector only (EV). Data are representative of at least three independent experiments (means ± S.D.), and identical results were obtained with the N-terminal-tagged and -untagged E4orf4.

View larger version (47K): [in this window] [in a new window]   FIG. 8. Cell death activities of wild-type and mutant E4orf4 proteins in C-33A cells. A, C-33A cells were transfected with the indicated E4orf4-GFP constructs and the morphological phenotypes of E4orf4-positive cells were analyzed by fluorescence microcopy 24 h after transfection. Arrow numbers indicate the two major cell death phenotypes observed for each E4orf4 proteins: arrowhead 1, blebbing phenotype characteristic of the cytoplasmic death activity; arrowhead 2, distinct regular cell rounding and shrinkage typical of the Src-independent death activity. The broad spectrum caspase inhibitor Boc-Asp-(OMe)CH2F (BocD-fmk) was added to the cultures during and after transfection to inhibit caspase activation in this particular cell line (15). Similar experiments were performed several times and analyzed in an unbiased way, by three independent investigators. Bars, 10 µm. B, C-33A cells were transfected with pGKpuro together with the vector alone, or the indicated E4orf4 constructs at a plasmid DNA ratio of 1:20, and cell survival assays were performed as described in the legend to Fig. 7B.

	DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Binding to the Kinase Domain of Src as a Dominant Mechanism to Deregulate Src Family Kinase Activity—To clarify the mechanisms by which E4orf4 deregulates Src tyrosine kinase signaling and how killing depends on Src, we have delineated the molecular determinants of a physical interaction between c-Src and E4orf4, showing that the Arg-rich motif of E4orf4 binds to the kinase domain of c-Src. Furthermore, we have provided convincing evidence that this physical interaction mediates E4orf4 deregulation of Src-dependent signaling and is required for triggering the cytoplasmic death program. Indeed, mutation of this Arg-rich motif completely ablated E4orf4-dependent modulation of Src phosphorylation, JNK activation, and the morphological changes that typify the cytoplasmic death pathway, without completely inhibiting E4orf4 functions (residual binding to PP2A-B and killing). Thus the possibility that this loss of function in cytoplasmic death activity may result from major misfolding problems is rather unlikely. The solubility of all the mutant E4orf4 proteins was similar to that of wild-type E4orf4, and immunofluorescence analyses confirmed that the proteins were not aggregated (data not shown). Based on these results, we propose that direct binding to the kinase domain of Src is the critical and rate-limiting step for activation of E4orf4 cytoplasmic death function. Src binding to the Arg-rich motif may allow the stable accumulation of E4orf4 in the cytoplasm and membranes. Indeed, E4orf4 preferentially accumulates in the nucleus when expressed in limited amounts (13), and the Arg-rich motif and surrounding sequences regulate its nuclear accumulation.² Binding to the Src kinase domain may mask some critical sequences required for nuclear import and promotes E4orf4 phosphorylation, a process that further stimulates its association with the membrane-cytoskeleton (13). These results indicated that the kinase domain of Src can support the formation of at least some E4orf4-Src signaling complexes (binding to phosphotyrosine proteins and cortactin), as well as E4orf4 phosphorylation in vitro and in vivo (data not shown). Thus the physical interaction may activate Src and subsequently the phosphorylation-dependent cytoplasmic activity of E4orf4. This is consistent with our previous findings suggesting that endogenous Src proteins associated with E4orf4 are activated (Tyr⁴¹⁶ phosphorylation), but that E4orf4 association with c-Src does not require E4orf4 tyrosine phosphorylation and Src catalytic activity (13). Most interactions with Src kinases occur through the SH2 and SH3 domains and disrupt the intramolecular interactions that maintain the kinases in a so-called inactive conformation (reviewed in Ref. 48). Few cellular ligands for Src kinase domain were reported, including the adaptor -arrestin 1 (49), the trimeric G proteins (50), and the Shc adaptor protein (51), but little is known regarding the physiological functions of such unusual protein-protein interactions taking place within the catalytic domain. However, there is evidence that they can activate the tyrosine kinase (52). We observed a modest 2-fold increase of Src activity (Tyr⁴¹⁶ phosphorylation) in E4orf4-expressing cell lysates relative to control cell lysates (data not shown). Considering that a limited fraction of E4orf4 is associated with cellular Src, this may well be significant. Thus available evidence strongly suggests that E4orf4 act by promoting specific Src signaling via binding to the kinase domain. Recruitment of active Src signaling complexes at specific membrane sites may deregulate critical Src functions in transformed cells, including actin dynamics (12).²

The first described ligand for Src kinase domain was another DNA virus protein, the transforming polyomavirus middle T-antigen (47). Similarly, polyomavirus middle T binding to the Src kinase domain leads to its tyrosine phosphorylation and subsequent recruitment and phosphorylation of cellular proteins (reviewed in Ref. 46). However, the final outcome is completely different, middle T transforms normal cells, whereas Ad2 E4orf4 kills transformed cells. The different outcomes are likely dictated by the nature of the signaling proteins being recruited to phosphorylated middle T versus phosphorylated Ad2 E4orf4. Indeed, mT does not tend to bind proteins involved in down modulation of signaling (e.g. GAP proteins), whereas E4orf4 does.² Our data also indicated that mT and E4orf4 differentially modulate the activity of the MAP kinase pathways ERK and JNK. Indeed, mT potently activates ERK, whereas E4orf4 does not, rather triggering a sustained activation of the JNK pathway in a Src-dependent manner. We have already shown that E4orf4 leads to inhibition of Src-Fak signaling and disorganization of focal adhesion complexes (12). This could be sufficient to block a cell survival signal linked to the regulation of cell shape, as Fak promotes survival through the activation of various signaling pathways, including ERK and PKB (53, 54). Whether the imbalance in MAP kinase signaling induced by E4orf4 contributes to cell death induction, or is only a consequence of E4orf4 ability to redirect Src signaling to specific targets/compartments and deregulate actin dynamics remains to be determined in future studies. Whatever the case, viral proteins have developed mechanisms to deregulate normal cellular functions in a way that cannot be restricted by other cellular factors. The observation that two viral proteins utilize a similar molecular mechanism to usurp Src functions is likely of physiological relevance. It could be that such a mode of Src regulation by other cellular factors plays a role during pathological cell proliferation and death processes. Despite intensive studies, Src functions in tumorigenesis and programmed cell death are still not clearly understood, and mT and E4orf4 will certainly provide powerful molecular tools for furthering our knowledge. It was reported that two basic motifs separated by negative charges, each followed by a serine or a threonine, are essential for middle T interaction with Src kinases (PKRRSEELRRAAT) (21). This motif is strikingly similar to the minimal sequence on E4orf4 that mediates binding to Src kinase domain in vitro (62-YYTERAKRRDRRRRSVCH-79). It will be interesting to determine whether other cellular ligands also use similar basic motifs and what sequences within Src kinase domain are involved.

Src and PP2A Signaling May Specify the Nature of E4orf4 Cell Death Activity in the Function of the Cellular Background—To identify the sequences that mediate binding to Src kinase domain and to delineate the contribution of Src to the cytoplasmic death pathway relative to overall cell killing, we have used E4orf4 mutant proteins characterized for their in vivo association with PP2A-B (18). In previous work, their killing activity was assessed by long term colony-forming assays. Here, we have considered more proximal effects, notably deregulation of Src phosphorylation, MAP kinase signaling, and induction of the dramatic blebbing phenotype. We believe that the results obtained add several findings of critical importance for interpretation of loss-of-function regarding E4orf4 mutants. In vitro binding assays revealed that mutation of the Arg-rich motif directly inhibits the molecular association with c-Src kinase domain, regardless of its putative effect on E4orf4 localization. Such mutations also affected, although to a lesser extent, the in vivo association with PP2A-B. Whether mutation of the Arg-rich motif affects PP2A-B binding at the molecular level, or if decreased Src binding and/or alteration of E4orf4 localization may account for decreased PP2A association in vivo is unclear. Given the lack of knowledge regarding the molecular determinants of the physical E4orf4-PP2A-B interaction in vitro and specific targets of E4orf4-PP2A-B in mammalian cells, we are unable yet to appreciate the real contribution of PP2A-B binding to the cytoplasmic death activity in the context of the wild-type E4orf4. Indeed, interactions between Src, PP2A, and E4orf4 are likely to be complexes in vivo, given that Src and PP2A can also interact with one another (36-40). This raises the possibility that E4orf4 may still associate with PP2A in the absence of direct binding to PP2A-B, in a Src-dependent manner. Additionally, Src can phosphorylate the catalytic subunit of PP2A and inhibit the phosphatase activity (37, 38, 40, 55). Because some E4orf4 complexes can contain both proteins, PP2A-C could well be a target of E4orf4-Src signaling. We have been unable to measure an increase in PP2A-C tyrosine phosphorylation in E4orf4-expressing cells (data not shown), but rapid autodephosphorylation in vitro may have hindered detection (55). Whatever the case, our data indicated that Src and PP2A associations are not mutually exclusive and suggested that they can cooperate to induce some of the specific E4orf4 activities and efficient cell killing in the context of wild-type E4orf4. Transient deactivation of PP2A by E4orf4-Src could enhance transmission of E4orf4-Src signals locally. Indeed, simultaneous binding to Src and PP2A could potentiate JNK activation and hyperphosphorylation of c-Jun by E4orf4, as suggested by the decrease in c-Jun hyperphosphorylation in cells expressing the R81A/F84A mutant relative to those expressing the wild-type E4orf4. Clarification of the exact nature of this cooperative signaling will require a better comprehension of the direct effects of E4orf4 on the phosphatase activity of PP2A.

Despite the complexity of E4orf4, Src, and PP2A signaling, we have succeeded in partially discriminating the functional roles of Src and PP2A-B binding in the cytoplasmic death program. This was achieved by using E4orf4 mutants still able to support efficient Src binding but completely defective for PP2A-B binding (R81A/F84A, F84A). Functional assays revealed that although PP2A signaling may contribute, E4orf4 binding to PP2A-B is not required to engage the cytoplasmic death pathway, which rather depends on the ability of E4orf4 to interact with the kinase domain of Src. Furthermore, the E4orf4 (F84A) mutant repeatedly showed a gain-of-function in cytoplasmic death activity, which correlated with a 2-fold increase in killing in 293T cells. Because binding to PP2A-B and Src does not appear to be competitive and binding to Src was not promoted, this mutation may rather increase E4orf4 association with and/or regulation of some other major targets in the cytoplasmic death pathway. Our preliminary work suggests that this gain-of-function is related to the ability of E4orf4 to modulate the Rho GTPases and actin dynamics.² Nonetheless, because residual killing remained upon inhibiting Src binding (this study) and Src tyrosine kinase activity (12, 15), a distinct cell death pathway independent of E4orf4 tyrosine phosphorylation exists, which appears to be critically dependent on PP2A-B binding, as reported previously (10, 18, 56). This distinct cell death pathway was more efficient in C-33A cells and was characterized by a distinct cell phenotype (cell shrinkage and lifting without membrane blebbing). Additionally, early cell death induced by E4orf4 (6R-A) and nonphosphorylatable E4orf4 in C-33A was not markedly inhibited by calpain inhibitors, whereas coexpression of calpastatin significantly inhibited the cytoplasmic cell death activity manifested by the wild-type and E4orf4 (R81A/F84A) mutant (data not shown), adding support for distinct death pathways, as previously reported (15). The loss of function manifested by E4orf4 (R81A/F84A), and the decreased efficiency of E4orf4 (6R-A) that correlated with its partial defect in PP2A-B binding, support a role for PP2A-B binding in engagement of this distinct cell death pathway. Importantly, both cell death activity contributed to overall killing in two different cell lines, although to a different extent: the cytoplasmic death activity was higher in 293T cells, whereas the phosphorylation-independent death activity was more predominant in C-33A cells. Although the existence of two distinct cell death pathways was suggested using a molecular targeting approach, this work provides the first evidence that they are manifested in the context of normal E4orf4 signaling within a given cell population. We believe that this work will provide critical information for future studies aimed at deciphering the specific effects of E4orf4 in normal versus transformed cells.

	FOOTNOTES

 
^* This work was supported by Grant MOP-49450 (to J. N. L.) from the Canadian Institutes of Health Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Recipient of a studentship from the National Sciences and Engineering Research Council of Canada.

Recipient of a studentship from the Canadian Institutes of Health Research.

^¶ A Junior 2 Scholar from the Fond de la Recherche en Santé du Québec (FRSQ). To whom correspondence should be addressed: CRC, L'Hôtel-Dieu de Québec, CHUQ, St-Patrick, 9 Rue McMahon, Québec G1R 2J6, Canada. Tel.: 418-525-4444, ext. 15120; Fax: 418-691-5439; E-mail: josee.lavoie{at}crhdq.ulaval.ca.

¹ The abbreviations used are: Ad2, adenovirus type 2; E4orf4, Ad2 early region 4 ORF4; GFP, green fluorescent protein; mT, polyomavirus middle T-antigen; GST, glutathione S-transferase; PBS, phosphate-buffered saline; SH, Src homology domain; ERK, extracellular signal-regulated kinase; MAP, mitogen-activated protein; JNK, Jun N-terminal kinase; FAK, focal adhesion kinase; fmk, fluoromethylketone; Boc, t-butoxycarbonyl; PP2A, protein phosphatase 2A.

² J. N. Lavoie and C. Champagne, unpublished results.

	ACKNOWLEDGMENTS

 
We thank Philip E. Branton, Stephen M. Dilworth, Joan S. Brugge, Michel Tremblay, Martin Stieger, and Thomas J. Parsons for providing expression constructs and bacterial strains. We thank André Lévesque for his assistance in microscopic and image analyses.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Tauber, B., and Dobner, T. (2001) Gene (Amst.) 278, 1-23[CrossRef][Medline] [Order article via Infotrieve]
2. Muller, U., Kleinberger, T., and Shenk, T. (1992) J. Virol. 66, 5867-5878[Abstract/Free Full Text]
3. Kleinb